FierceBiotechOriginal article
{"a":[{"_":"Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies","$":{"href":"/biotech/eli-lilly-inks-29b-merida-buyout-autoimmune-drugs-against-rogue-antibodies","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Eli Lilly has agreed to acquire Merida Biosciences for up to $2.875 billion to gain access to technology for treating autoimmune diseases through selective degradation of pathogenic autoantibodies.
Importance:7/10
Sentiment:
0.70
acquisitionM&AautoimmuneEli LillyMerida Biosciencesantibody degradation
Read the original article
Published by FierceBiotech on August 31, 2026 8:04 AM